Bionomics Limited (BNOX) Files for US IPO

Bionomics Limited (NASDAQ: BNOX) has filed for a US IPO.

The company describes itself as: "We are a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Ion channels serve as important mediators of physiological function in the CNS and the modulation of ion channels influences neurotransmission that leads to downstream signaling in the brain. The α7 nicotinic acetylcholine (“ACh”) receptor (“α7 receptor”) is an ion channel that plays an important role in driving emotional responses and cognitive performance. Utilizing our expertise in ion channel biology and translational medicine, we are developing orally active small molecule negative allosteric modulators (“NAMs”) and positive allosteric modulators (“PAMs”) of the α7 receptor to treat anxiety and stressor-related disorders and cognitive dysfunction, respectively."

Evercore ISI, William Blair and Cantor will serve as lead underwriters.

You May Also Be Interested In

• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• Avalanche Treasury Co. begins trading on NASDAQ under ticker AVAT
• OpenAI to acquire cloud execution company Ona